Journals / Akademik Acil Tıp Dergisi / 2013 / Cilt: 12 - Sayı: 3

Varfarin kullanan hastalarda meydana gelen komplikasyonların demografik analizi ve mortalite üzerine etkili faktörler

Demographic analysis of complications of warfarin treatment and factors affecting mortality

Pages
139–144
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

PT and INR levels were significantly higher in patients with hemorrhage compared to those without (for PT 90.98±26.52 vs. 55.51±12.70, respectively; p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study investigated the demographic analysis of complications of warfarin therapy and the factors affecting mortality.
📊
Key Findings & Data:Material and Methods: The digital medical records of patients who applied to our Emergency Clinic with warfarin overdose between September 2007 and September 2010 were retrieved and patient files were assessed retrospectively.
💡
Conclusion & Impact:PT and INR levels were significantly higher in patients with hemorrhage compared to those without (for PT 90.98±26.52 vs. 55.51±12.70, respectively; p
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: This study investigated the demographic analysis of complications of warfarin therapy and the factors affecting mortality. Material and Methods: The digital medical records of patients who applied to our Emergency Clinic with warfarin overdose between September 2007 and September 2010 were retrieved and patient files were assessed retrospectively. Cases were classified into two groups in terms of INR level and hemorrhagic complications; patients with an INR level greater than 3.5 and a hemorrhagic complication, and patients with an INR level greater than 3.5 and no hemorrhagic complication. Furthermore, cases with a hemorrhagic complication were divided into two subgroups as those who died and those who survived. Results: The study enrolled 151 cases presenting to our emergency clinic with warfarin overdose. Among these, 50.3% (n=76) were males and 49.7% (n=75were females. Mean age was 60.80±16.11 years. There was no significant dif- ference between the groups in terms of sex and age. Hemorrhagic complica- tion was present in 66.89% (n=101) while absent in 33.11% (n=50). PT and INR levels were significantly higher in patients with hemorrhage compared to those without (for PT 90.98±26.52 vs. 55.51±12.70, respectively; p

Özet

Amaç: Bu çalışmada varfarin kullanan hastalarda meydana gelen komplikasyonların demografik analizi ve mortalite üzerine etkili faktörler araştırılmıştır. Gereç ve Yöntemler: Acil servisimize Eylül 2007-Eylül 2010 tarihleri arasında varfarin yüksek dozu nedeni ile başvuran hastalar bilgisayar kayıtlarından tespit edildi ve bu hastaların dosyaları arşivimizden bulunarak geriye dönük olarak incelendi. Çalışmaya dahil edilen olgular varfarin kullanımına bağlı INR değeri 3,5in üstü olup kanama komplikasyonu gelişenler ve varfarin kullanımına bağlı INR değeri 3,5in üstü olup herhangi bir kanama komplikasyonu gelişmeyenler olarak iki gruba ayrıldı. Ayrıca kanama komplikasyonu gelişen olgular kendi içinde ölenler ve sağ kalanlar olarak ikiye ayrılarak karşılaştırıldı. Bulgular: Çalışmaya, hastanemiz acil servisine Eylül 2007 ile Eylül 2010 tarihleri arasında varfarin overdozu nedeniyle başvuran 151 olgu dahil edildi. Bunların %50,3ü (n=76) erkek ve %49,7si (n=75) kadındı. Ortalama yaş tüm hastalar için 60,80±16,11 idi. İstatistiksel olarak gruplar arasında cinsiyet ve yaş açısından anlamlı bir fark yoktu. Hastaların %66,89u (n=101) kanama komplikasyonu gelişen, %33,11i (n=50) ise kanama komplikasyonu gelişmeyen olgular idi. Kanama komplikasyonu gelişen hastalarımızda gelişmeyenlere göre PT ve INR değeri anlamlı derecede daha yüksekti (sırasıyla PT için 90,98±26,52 ve 55,51±12,70 p

🔖

Cite This Article

DURSUN, R., ÖZHASENEKLER, A., GÜLOĞLU, C., ORAK, M., ÜSTÜNDAĞ, M., DURGUN, H. M. (2022). Varfarin kullanan hastalarda meydana gelen komplikasyonların demografik analizi ve mortalite üzerine etkili faktörler. Akademik Acil Tıp Dergisi, Cilt: 12 - Sayı: 3, 139–144. https://ajindex.com/articles/431632

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Garcia DA, Regan S, Crowther M, Hylek EM. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol 2006; 47: 804-8. [CrossRef] Buckingham TA, Hatala R. Anticoagulants for atrial fibrillation: why is the treatment rate so low. Clin Cardiol 2002; 25: 447-54. [CrossRef] Süzer Ö. Farmakolojinin temelleri. s.381, 2. Basım, Nobel Tıp Kitapevleri, İstanbul, 2002.
  2. Gunnar H N, Ingela B, Hans J. Anticoagulant treatment in primary health care in Sweden –prevalence, incidence and treatment diagnosis: a retros- pectivestudy on electronic patient records in a registered population. BMC Family Practice 2003; 4: 3. [CrossRef] Denizbaşı A, Unluer EE, Güneysel Ö, Eroğlu S, Koşargelir M. Complications of warfarin therapy and the correlation of the outcomes with INR levels. J Emerg Med 2006; 30: 241-2. [CrossRef] Fanikos J, Grasso-Correnti N, Shah R, Kucher N, Goldhaber SZ. Major ble- eding complications in a specialized anticoagulation service. Am J Cardiol 2005; 96: 595-8. [CrossRef] Baydın A, Nargıs C, Karataş D, Güven H, Doğanay Z, Yardan T. Retrospective evaluation of patients used warfarin admitted to emergency depart- ment. Turk J Emerg Med 2006; 6: 56-9.
  3. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, pros- pective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8. [CrossRef] Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorr- hage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141: 745-52. [CrossRef] Yasaka MK, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of s troke in patients with non-valvular atrial fibrillation. Intern Med 2001; 40: 1183-8. [CrossRef] Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57. [CrossRef] Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpati- ents taking warfarin. Ann Intern Med 1994; 120: 897-902. [CrossRef] Albers GW. Atrial fibrillation and stroke: three new studies three remai- ning questions. Arch Intern Med 1994; 154: 1443-8. [CrossRef] Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D